Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (411-420 of 752) with videos related to

Pageof 76
Sort By:
European Heart Journal|July 10, 2009
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysisPeter R Sinnaeve, Justin A Ezekowitz, Kris Bogaerts, et al.
Thrombosis and Haemostasis|March 31, 2010
Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusionMariann Gyöngyösi, Aniko Posa, Noemi Pavo, et al.
BMJ Open|April 1, 2019
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)Miklos Rohla, Thomas W Weiss, Ladislav Pecen, et al.
Journal of Thrombosis and Thrombolysis|September 13, 2019
Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAxel Åkerblom, Daniel Wojdyla, Philippe Gabriel Steg, et al.
American Heart Journal|January 28, 2010
Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trialRudolf Jarai, Kurt Huber, Kris Bogaerts, et al.
Circulation|April 1, 2009
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trialJulinda Mehilli, Adnan Kastrati, Stefanie Schulz, et al.
Cells|January 21, 2022
Biomarkers-in-Cardiology 8 RE-VISITED-Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome-A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 TrialEvangelos Giannitsis, Tania Garfias-Veitl, Anna Slagman, et al.
The American Journal of Cardiology|July 24, 2017
Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin TherapyIoannis Tentzeris, Serdar Farhan, Matthias Karl Freynhofer, et al.
European Heart Journal|May 27, 2010
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trialKurt Huber, David R Holmes, Arnoud W van 't Hof, et al.
European Heart Journal. Imaging Methods and Practice|March 30, 2026
Diagnostic performance of combined biomarkers and phonocardiography vs. the 2024 ESC risk factor-weighted clinical likelihood model for detecting coronary artery diseaseMarie Muthspiel, Mahdi Mahmoudi, Moritz Hebein, et al.
Pageof 76

Showing results (411-420 of 752) with videos related to

Sort By:
Pageof 76
European Heart Journal|July 10, 2009
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysisPeter R Sinnaeve, Justin A Ezekowitz, Kris Bogaerts, et al.
Thrombosis and Haemostasis|March 31, 2010
Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusionMariann Gyöngyösi, Aniko Posa, Noemi Pavo, et al.
BMJ Open|April 1, 2019
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)Miklos Rohla, Thomas W Weiss, Ladislav Pecen, et al.
Journal of Thrombosis and Thrombolysis|September 13, 2019
Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAxel Åkerblom, Daniel Wojdyla, Philippe Gabriel Steg, et al.
American Heart Journal|January 28, 2010
Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trialRudolf Jarai, Kurt Huber, Kris Bogaerts, et al.
Circulation|April 1, 2009
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trialJulinda Mehilli, Adnan Kastrati, Stefanie Schulz, et al.
Cells|January 21, 2022
Biomarkers-in-Cardiology 8 RE-VISITED-Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome-A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 TrialEvangelos Giannitsis, Tania Garfias-Veitl, Anna Slagman, et al.
The American Journal of Cardiology|July 24, 2017
Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin TherapyIoannis Tentzeris, Serdar Farhan, Matthias Karl Freynhofer, et al.
European Heart Journal|May 27, 2010
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trialKurt Huber, David R Holmes, Arnoud W van 't Hof, et al.
European Heart Journal. Imaging Methods and Practice|March 30, 2026
Diagnostic performance of combined biomarkers and phonocardiography vs. the 2024 ESC risk factor-weighted clinical likelihood model for detecting coronary artery diseaseMarie Muthspiel, Mahdi Mahmoudi, Moritz Hebein, et al.
Pageof 76